Treatment Effect of Ergocalciferol on Bone Metabolism Indexes and Parathyroid Hormone in Hemodialysis Patients

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

In this study the researchers aimed to evaluate the effects of treatment with ergocalciferol on bone metabolism indexes in hemodialysis patients.

Why It Was Studied

Vitamin D deficiency is a common problem in end-stage renal disease patients under hemodialysis.

Both active and nutritional vitamin D supplementation have been recommended for its treatment.

Who Took Part

According to the abstract, 40 patients were involved.

The age groups tagged for this paper are young adults, adults, middle-aged adults and older adults, both men and women.

In a randomized controlled trial, 40 hemodialysis patients were randomly allocated to the intervention (n = 20) and placebo (n = 20) groups.

During the study, 4 patients in the placebo and 1 in the intervention group were excluded.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Parathyroid Hormone (PTH 1-84) could be set against what happens without it.

Serum levels of 25-hydroxyvitamin D, calcium, parathyroid hormone, and alkaline phosphatase were measured before and after treatment.

What Was Measured

Topics PubMed links to this paper include Alkaline Phosphatase, Calcitriol, Calcium-Regulating Hormones and Agents, Ergocalciferols, Kidney Failure, Chronic, Parathyroid Hormone and Renal Dialysis.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 40 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Iranian journal of kidney diseases), a journal based in Iran.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.